Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5′-O-(α -boranotriphosphate) analogues
- 1 October 2006
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 416-423
- https://doi.org/10.1038/sj.bjp.0706887
Abstract
We explored the stereoselective activation of the P2Y11 receptor, stably expressed and tagged with GFP, in 1321N1 cells, in comparison to its closest homologue, the P2Y1 receptor. The potency of several chiral ATP analogues was determined by measuring increases in intracellular calcium concentration ([Ca2+]i). In a series of ATP-alpha-B and ATP-alpha-S analogues, a non-bridging oxygen atom of Palpha was substituted by BH3 or sulphur, respectively, introducing a chiral center at Palpha. The pairs of diastereoisomers (A and B isomers) were each applied as purified compounds. The (B) isomers (ATP-alpha-B Sp isomers and ATP-alpha-S Rp isomers) of all derivatives tested were more potent at the P2Y11 receptor than the corresponding (A) isomers (ATP-alpha-B Rp isomers and ATP-alpha-S Sp isomers) and the parent compounds. This characteristic of the P2Y11 receptor is opposite to the behaviour of the same diastereoisomers at the P2Y1 receptor, at which the (A) isomers are more active. The distinctly opposite diastereoselective activity of ATP derivatives at the P2Y11 and the P2Y1 receptor will allow the deciphering of structural differences of the ligand recognition sites between these receptor subtypes and may aid in the development of subtype-selective agonists. Moreover, ATP-alpha-B diastereoisomers are not active at the P2Y2 receptor. Thus, they are compounds suitable for distinguishing the functional contribution of the two ATP-activated P2Y receptors, the P2Y2 and P2Y11 receptor, in physiological or pathophysiological responses of cells.Keywords
This publication has 24 references indexed in Scilit:
- Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5′-triphosphate analogues at the human P2Y2 and P2Y4 receptorsBiochemical Pharmacology, 2006
- Molecular Recognition in Purinergic Receptors. 1. A Comprehensive Computational Study of the h-P2Y1-ReceptorJournal of Medicinal Chemistry, 2004
- Molecular Recognition in Purinergic Receptors. 2. Diastereoselectivity of the h-P2Y1-ReceptorJournal of Medicinal Chemistry, 2004
- Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5′‐O‐(1‐boranotriphosphate) derivativesBritish Journal of Pharmacology, 2004
- Characterization of a Ca2+ Response to Both UTP and ATP at Human P2Y11 Receptors: Evidence for Agonist-Specific SignalingMolecular Pharmacology, 2003
- Mechanisms of P2X7receptor-mediated ERK1/2 phosphorylation in human astrocytoma cellsAmerican Journal of Physiology-Cell Physiology, 2003
- Adenosine 5‘-O-(1-Boranotriphosphate) Derivatives as Novel P2Y1 Receptor AgonistsJournal of Medicinal Chemistry, 2002
- Methanocarba Modification of Uracil and Adenine Nucleotides: High Potency of Northern Ring Conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but Not P2Y6 ReceptorsJournal of Medicinal Chemistry, 2001
- The P2Y11 Receptor Mediates the ATP-Induced Maturation of Human Monocyte-Derived Dendritic CellsThe Journal of Immunology, 2001
- Pharmacological characterization of the human P2Y11 receptorBritish Journal of Pharmacology, 1999